Doctronic Secures $40M, Propelling AI Healthcare Revolution
March 30, 2026, 3:51 am
Location: United States, California, Menlo Park
Employees: 51-200
Founded date: 2000
Doctronic, a New York City-based AI healthcare innovator, just secured $40 million in Series B funding, bringing its total capital to $65 million. This AI system legally practices medicine across all 50 states. It boasts 15x revenue growth, serving over 300,000 weekly users. Funds will propel expansion into pediatrics, forge new partnerships, and broaden AI-powered prescription renewals. The platform offers 24/7 free AI consultations and paid physician visits, embodying a new era of accessible, efficient, and thorough medical care. Doctronic leads the charge in autonomous AI, redefining healthcare delivery nationwide.
Doctronic, a pioneer in AI-driven healthcare, recently announced a significant financial milestone. The New York City-based firm closed a $40 million Series B funding round. This infusion elevates its total capital raised to an impressive $65 million. The investment underscores strong confidence in Doctronic's innovative approach to medical practice.
The Series B round saw co-leadership from prominent venture capital firms Abstract and Lightspeed Venture Partners. Existing investors also participated, including Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures. This widespread investor support highlights the recognized potential of Doctronic's autonomous AI system. The funding will fuel aggressive expansion and product development.
Doctronic stands at the forefront of medical AI. It developed an artificial intelligence system legally authorized to practice medicine in the United States. This unique status positions Doctronic as a critical player in the evolving digital health landscape. Dr. Adam Oskowitz and Matt Pavelle co-founded the company with a vision for transformative patient care.
The company has experienced explosive growth. In less than six months since its Series A, Doctronic reported a staggering 15x growth. It now generates eight-figure annualized revenue. This rapid ascent reflects robust market demand for its AI-powered services. User engagement also surged. Doctronic now attracts over 300,000 weekly visitors. Its repeat patient rate has nearly tripled, demonstrating strong patient satisfaction and loyalty.
A pivotal achievement occurred in December 2025. Doctronic became the first AI-native platform to autonomously renew prescriptions. This landmark event took place under Utah’s progressive AI Learning Lab regulatory sandbox. The system currently supports prescription renewals for 190 different medications. Built-in safety protocols ensure patient well-being. The AI escalates cases to licensed physicians when necessary. Doctronic is actively engaging regulators. It seeks to expand its AI-powered prescription services beyond Utah. This move promises wider access to efficient medication management.
Doctronic operates its own comprehensive clinical practice. This practice holds licenses in all 50 states. It provides nationwide coverage. The platform is fully HIPAA-compliant, ensuring patient data privacy and security. Services are available 24/7. Users can access free AI consultations. They can also schedule paid physician video visits for more complex needs. This accessibility democratizes healthcare.
The core of Doctronic’s innovation lies in its advanced technology. It employs a collective intelligence architecture. A sophisticated multi-agent system drives its operations. This AI integrates vast amounts of patient data. It processes medical records, medication histories, and drug interaction screenings. The system then conducts structured clinical reasoning. This meticulous process mirrors human diagnostic rigor.
Safety remains paramount. Doctronic’s AI performs dozens of safety checks for each prescription renewal. A human physician would require an hour for comparable diligence. The platform boasts an impressive 99.2% treatment alignment rate. This figure reflects real-world patient outcomes in actual clinical scenarios. Furthermore, Doctronic maintains a first-of-its-kind AI medical malpractice insurance program. This initiative allows its AI to operate independently with accountability. It sets a new standard for AI responsibility in medicine.
The new funding will power strategic expansion initiatives. Doctronic plans to forge robust partnerships. These include collaborations with hospital systems, academic institutions, digital health platforms, and payers. Such alliances will embed Doctronic’s AI capabilities across the healthcare ecosystem. The company will also expand into new areas, notably pediatrics. Continued product development remains a core focus. This investment reinforces Doctronic's commitment to advancing AI in medicine.
Doctronic offers a compelling vision for the future of healthcare. Its AI provides care that is faster and more cost-effective. It is also remarkably more thorough than traditional methods. For health systems, Doctronic acts as essential infrastructure. It serves as a digital front door, efficiently routing patients and keeping care within network. Payers see Doctronic as a solution for unlimited primary care at predictable costs. Patients gain unprecedented access to expert medical insights and care.
Doctronic's trajectory is clear. It leads the charge in autonomous AI healthcare. Its proven clinical rigor and market demand are undeniable. The company's commitment to responsibility and outcomes defines its leadership. This latest funding round solidifies its position. Doctronic is not just developing technology. It is redefining how millions access and experience medical care nationwide. The future of healthcare is here, powered by AI.
Doctronic, a pioneer in AI-driven healthcare, recently announced a significant financial milestone. The New York City-based firm closed a $40 million Series B funding round. This infusion elevates its total capital raised to an impressive $65 million. The investment underscores strong confidence in Doctronic's innovative approach to medical practice.
The Series B round saw co-leadership from prominent venture capital firms Abstract and Lightspeed Venture Partners. Existing investors also participated, including Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures. This widespread investor support highlights the recognized potential of Doctronic's autonomous AI system. The funding will fuel aggressive expansion and product development.
Doctronic stands at the forefront of medical AI. It developed an artificial intelligence system legally authorized to practice medicine in the United States. This unique status positions Doctronic as a critical player in the evolving digital health landscape. Dr. Adam Oskowitz and Matt Pavelle co-founded the company with a vision for transformative patient care.
The company has experienced explosive growth. In less than six months since its Series A, Doctronic reported a staggering 15x growth. It now generates eight-figure annualized revenue. This rapid ascent reflects robust market demand for its AI-powered services. User engagement also surged. Doctronic now attracts over 300,000 weekly visitors. Its repeat patient rate has nearly tripled, demonstrating strong patient satisfaction and loyalty.
A pivotal achievement occurred in December 2025. Doctronic became the first AI-native platform to autonomously renew prescriptions. This landmark event took place under Utah’s progressive AI Learning Lab regulatory sandbox. The system currently supports prescription renewals for 190 different medications. Built-in safety protocols ensure patient well-being. The AI escalates cases to licensed physicians when necessary. Doctronic is actively engaging regulators. It seeks to expand its AI-powered prescription services beyond Utah. This move promises wider access to efficient medication management.
Doctronic operates its own comprehensive clinical practice. This practice holds licenses in all 50 states. It provides nationwide coverage. The platform is fully HIPAA-compliant, ensuring patient data privacy and security. Services are available 24/7. Users can access free AI consultations. They can also schedule paid physician video visits for more complex needs. This accessibility democratizes healthcare.
The core of Doctronic’s innovation lies in its advanced technology. It employs a collective intelligence architecture. A sophisticated multi-agent system drives its operations. This AI integrates vast amounts of patient data. It processes medical records, medication histories, and drug interaction screenings. The system then conducts structured clinical reasoning. This meticulous process mirrors human diagnostic rigor.
Safety remains paramount. Doctronic’s AI performs dozens of safety checks for each prescription renewal. A human physician would require an hour for comparable diligence. The platform boasts an impressive 99.2% treatment alignment rate. This figure reflects real-world patient outcomes in actual clinical scenarios. Furthermore, Doctronic maintains a first-of-its-kind AI medical malpractice insurance program. This initiative allows its AI to operate independently with accountability. It sets a new standard for AI responsibility in medicine.
The new funding will power strategic expansion initiatives. Doctronic plans to forge robust partnerships. These include collaborations with hospital systems, academic institutions, digital health platforms, and payers. Such alliances will embed Doctronic’s AI capabilities across the healthcare ecosystem. The company will also expand into new areas, notably pediatrics. Continued product development remains a core focus. This investment reinforces Doctronic's commitment to advancing AI in medicine.
Doctronic offers a compelling vision for the future of healthcare. Its AI provides care that is faster and more cost-effective. It is also remarkably more thorough than traditional methods. For health systems, Doctronic acts as essential infrastructure. It serves as a digital front door, efficiently routing patients and keeping care within network. Payers see Doctronic as a solution for unlimited primary care at predictable costs. Patients gain unprecedented access to expert medical insights and care.
Doctronic's trajectory is clear. It leads the charge in autonomous AI healthcare. Its proven clinical rigor and market demand are undeniable. The company's commitment to responsibility and outcomes defines its leadership. This latest funding round solidifies its position. Doctronic is not just developing technology. It is redefining how millions access and experience medical care nationwide. The future of healthcare is here, powered by AI.